Exchange: NASDAQ·Updated 07:57 PM EDT
EXEL logo

EXELExelixis Inc

$55.37
$0.28
(0.50%)
Today
Closed $55.37
$0.37
(0.67%)
After Hours
EarningsAug 5
Mkt Cap$13.92B
Vol1.84M
News
all
press releases
EXEL vs. ILMN: Which Stock Is the Better Value Option?
EXEL vs. ILMN: Which Stock Is the Better Value Option?
Zacks
More News
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2026 financial results will be released on Wednesday, August 5, 2026 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a...
Business Wire
Alkermes (ALKS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks
J&J Q2 Earnings Beat on Darzalex, Tremfya Growth, 2026 Outlook Raised
JNJ tops Q2 earnings and sales estimates, driven by key drug growth, and raises its 2026 outlook despite a slight MedTech sales miss.
Zacks
Zacks Investment Ideas feature highlights: XLV, XBI, LLY, EXEL, PTCT, FTRE and ILMN
Biotech is gaining momentum as healthcare leads higher, with several drugmakers and life sciences companies showing improving earnings trends and breakouts.
Zacks
EXEL Stock Soars 26.8% in Three Months: Is There More Room for Growth?
Exelixis' zanzalintinib faces a setback, but an FDA review, phase III trials and Cabometyx momentum keep investors focused on its growth path.
Zacks
Stocks Look Shaky, But This Sector is Booming (Biotech)
Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market leaders.
Zacks
Here's Why Exelixis (EXEL) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
<
1
2
...
>

Advertisement|Remove ads.